Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations
18 April 2023 - 9:00PM
Business Wire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patients’ lives by
developing and commercializing innovative products across a range
of therapies, today announced that the U.S. Patent and Trademark
Office has issued US Patent Number 11,590,205, entitled ‘METHODS
FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC
POLAR SOLVENTS.’ The claims in this newly issued patent cover
certain pharmaceutical formulations in Xeris’ Gvoke® product line,
methods of use of such formulations in treating hypoglycemia, and
methods of manufacturing the therapeutic formulations.
“Xeris’ strategy is to patent early and often, including through
a castle/moat approach that has led to numerous filings both at the
platform and product levels. The addition of this new patent
further strengthens our intellectual property position in the
XeriSol™ platform portion of our portfolio and has claims that will
cover the Gvoke formulation, which is in all our currently marketed
Gvoke products,” said Paul R. Edick, Xeris’ Chairman and CEO.
The Xeris patent portfolio consists of 178 total patents
globally, of which 33 are U.S. issued; 128 patent applications
pending globally, of which 21 are pending in the U.S.; and 60
patents pertaining to its technology platform. Xeris’ XeriSol
patent portfolio includes patents and applications directed to this
platform formulation technology, commercial and pipeline
pharmaceutical product formulations, and therapeutic methods using
such formulations to treat a variety of human diseases and
disorders. All patents are owned by Xeris Biopharma
subsidiaries.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical
company committed to improving patients’ lives by developing and
commercializing differentiated and innovative products across a
range of therapies. Xeris has three commercially available
products: Gvoke®, a ready-to-use liquid glucagon for the treatment
of severe hypoglycemia; Keveyis®, a proven therapy for primary
periodic paralysis; and Recorlev® for the treatment of endogenous
Cushing’s syndrome. Xeris has a diverse pipeline of development and
partnered programs using its formulation sciences, XeriSol™ and
XeriJect™ to support long-term product development and commercial
success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For
more information, visit www.xerispharma.com, or follow us on
Twitter, LinkedIn or Instagram.
Forward-Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Xeris Biopharma Holdings, Inc. including
statements regarding the strength of its intellectual property
position in the XeriSol™ platform portion of its portfolio,
prospects for the issuance of patents, , the market and therapeutic
potential of its products and product candidates, its ability to
successfully develop and commercialize differentiated and
innovative products, continued use of its formulation sciences by
development and partnered programs, the potential utility of its
formulation platforms, and other statements containing the words
“will,” “would,” “continue,” “expect,” and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on numerous assumptions and
assessments made in light of Xeris’ experience and perception of
historical trends, current conditions, business strategies,
operating environment, future developments, geopolitical factors
and other factors it believes appropriate. By their nature,
forward-looking statements involve known and unknown risks and
uncertainties because they relate to events and depend on
circumstances that will occur in the future. The various factors
that could cause Xeris’ actual results, performance or
achievements, industry results and developments to differ
materially from those expressed in or implied by such
forward-looking statements, include the impact of COVID-19 on its
business operations and clinical activities, our financial position
and need for financing, including to fund its product development
programs or commercialization efforts, whether its products will
achieve and maintain market acceptance, its reliance on third-party
suppliers, including single-source suppliers, its reliance on third
parties to conduct clinical trials, the ability of its product
candidates to compete successfully with existing and new drugs, and
its and collaborators’ ability to protect our intellectual property
and proprietary technology. No assurance can be given that such
expectations will be realized and persons reading this
communication are, therefore, cautioned not to place undue reliance
on these forward-looking statements. Additional information about
potential impacts of COVID-19, financial, operational, economic,
competitive, regulatory, governmental, technological, and other
factors that may affect Xeris is set forth in the "Risk Factors"
section of Xeris’ most recently filed Quarterly Report on Form 10-Q
filed with the Securities and Exchange Commission, the contents of
which are not incorporated by reference into, nor do they form part
of, this communication. Forward-looking statements in this
communication are based on information available to us, as of the
date of this communication and, while believed to be reasonable,
actual results may differ materially. Subject to any obligations
under applicable law, we do not undertake any obligation to update
any forward-looking statement whether as a result of new
information, future developments or otherwise, or to conform any
forward-looking statement to actual results, future events, or to
changes in expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230418005445/en/
Investor Contact Allison Wey Senior Vice President,
Investor Relations and Corporate Communications
awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Apr 2023 to Apr 2024